The Business Research Company’s report on the Beyfortus Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How have key drivers contributed to the rapid growth of the beyfortus market?
Increasing incidence of RSV cases is expected to propel the growth of the beyfortus market going forward. Respiratory syncytial virus (RSV) is a highly contagious virus that primarily infects the respiratory tract, causing illnesses such as bronchiolitis and pneumonia, especially in infants, young children, older adults, and immunocompromised individuals. RSV cases are increasing due to delayed exposure from pandemic restrictions, shifts in virus seasonality, lower immunity in children, and increased social interactions. Beyfortus helps reduce RSV cases by providing passive immunity through a single-dose monoclonal antibody, nirsevimab, which targets and neutralizes the respiratory syncytial virus, thereby preventing severe lower respiratory tract infections in newborns and infants during their first RSV season. For instance, in June 2024, according to the National Library of Medicine, a US-based medical library, between 2021 and 2023, the number of RSV patients increased by 2.4 times (95% confidence interval [CI]: 1.7, 3.5) compared to the pre-pandemic period, while RSV test volume saw an 18.9-fold increase (95% CI: 15.0, 23.9). Therefore, increasing incidence of RSV cases drives the growth of the beyfortus market.
Access Your Free Sample of the Global Beyfortus Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=19999&type=smp
How has the beyfortus market size evolved, and what are the latest forecasts for its expansion?
The beyfortus market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to a rise in the need for effective infant prophylaxis, increased demand for long-acting monoclonal antibodies, increased global awareness of respiratory diseases, geographic expansion, and increased focus on infant health.
The beyfortus market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to the increasing burden of respiratory syncytial virus (RSV) infections, increasing medical need for RSV prevention, rising interest from healthcare providers, increasing influence of health policy, and increasing diversity in clinical trials. Major trends in the forecast period include AI for drug development, telemedicine and remote monitoring, regenerative medicine, wearable technologies and biosensors, and gene editing and CRISPR technology.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=19999&type=smp
Which major companies dominate the beyfortus market?
Major companies operating in the beyfortus market include AstraZeneca plc; Sanofi SA
What trends will shape the future of the bexsero market?
The key trend in the beyfortus market is focusing on developing innovative drugs, such as human IgG1? antibodies, to provide high stability, the ability to efficiently bind to antigens, and strong activation of immune responses. Human IgG1? antibody is a subtype of the IgG immunoglobulin class, characterized by its specific structure and function in immune responses, including binding to antigens and activating immune cells. For instance, in July 2023, Sanofi SA, a France-based healthcare company, together with AstraZeneca Plc, a UK-based pharmaceutical and biotechnology company, announced the Beyfortus (nirsevimab-alip), which was approved by the Food and Drug Administration (FDA), a US-based federal agency. It is recommended for preventing lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in newborns and infants during their first RSV season, as well as for children up to 24 months old who are at continued risk of severe RSV disease during their second RSV season. The FDA’s approval of Beyfortus comes after a positive recommendation from the FDA Antimicrobial Drugs Advisory Committee and is supported by an extensive clinical development program, including three pivotal late-stage trials. In these trials, a single dose of Beyfortus showed high and consistent efficacy against RSV LRTD, providing protection for up to five months, the typical length of an RSV season. Additionally, Beyfortus was well tolerated, with a safety profile that remained favorable and consistent across all clinical trials.
Which region dominates the beyfortus market, and what factors contribute to its leadership?
North America was the largest region in the beyfortus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the beyfortus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/beyfortus-global-market-report
How is the beyfortus market segmented, and which segment holds the largest share?
The beyfortus market covered in this report is segmented –
1) By Indication: Respiratory Syncytial Virus (RSV) Prevention, Infant Care
2) By Age Group: Infants And Neonates, Children, Elderly Population
3) By Distribution Channel: Hospitals, Pharmacies, Public Health Programs
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19999
How is the beyfortus market defined, and what are its core characteristics?
Beyfortus refers to a monoclonal antibody medication (nirsevimab) designed to provide passive immunity against respiratory syncytial virus (RSV). It is used for the prevention of RSV lower respiratory tract infections in newborns and infants during their first RSV season, offering long-lasting protection with a single dose.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
